伤口感染,抗生素抗性细菌病原体的流行加剧了,需要创新的抗菌方法。多微生物感染,通常涉及铜绿假单胞菌和耐甲氧西林金黄色葡萄球菌(MRSA),由于生物膜的形成和抗生素耐药性,目前的挑战。次氯酸(HOCl),一种有效的抗菌剂,有望成为替代疗法。评估了通过微型恒电位仪控制的精确极化原位产生HOCl的电化学绷带(电子绷带),用于治疗包含具有“难以治疗”抗性的铜绿假单胞菌和MRSA的鼠伤口生物膜感染。以前,产生HOCl的电子绷带显示减少仅含有铜绿假单胞菌的鼠伤口生物膜。这里,在含有包含MRSA和铜绿假单胞菌的48小时生物膜的5毫米切除皮肤伤口中,极化电子绷带治疗与非极化电子绷带治疗(无HOCl产生)相比,MRSA减少1.1log10CFU/g(P=0.026),和1.4log10CFU/g(0.0015)与仅Tegaderm对照;铜绿假单胞菌同样降低了1.6log10CFU/g(P=0.0032)和1.6log10CFU/g(P=0.0015),分别。对于单独感染MRSA的伤口,与非极化电子绷带和仅Tegaderm相比,极化电子绷带治疗可将细菌负荷降低1.1log10CFU/g(P=0.0048)和1.3log10CFU/g(P=0.0048),分别。电子绷带治疗没有负面影响伤口愈合或引起组织毒性。全身性抗生素的添加并未增强电子绷带的抗微生物功效。这项研究为产生HOCl的电子绷带提供了额外的证据,作为管理伤口感染的新型抗菌策略,包括抗生素耐药性和多微生物感染。
目的:需要新的方法来对抗抗菌药物耐药感染的上升。产生HOCl的电化学绷带(电子绷带)利用HOCl的原位生成,一种天然的杀生物剂,用于广谱杀灭伤口病原体。与传统疗法不同,传统疗法可能对生物膜和抗微生物药物具有有限的活性,电子绷带提供了一种有效的,不导致进一步耐药或需要辅助抗生素治疗的独立解决方案。这里,我们展示了电子绷带解决由金黄色葡萄球菌和铜绿假单胞菌的抗菌耐药临床分离株的多微生物感染的能力,两个通常是孤立的,共同感染伤口病原体。产生HOCl的电子绷带在减少病原体负荷同时最小化组织毒性和避免对全身性抗生素的需要方面的有效性强调了其作为管理复杂伤口感染的工具的潜力。
Wound infections, exacerbated by the prevalence of antibiotic-resistant bacterial pathogens, necessitate innovative antimicrobial approaches. Polymicrobial infections, often involving Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA), present challenges due to biofilm formation and antibiotic resistance. Hypochlorous acid (HOCl), a potent antimicrobial agent, holds promise as an alternative therapy. An electrochemical bandage (e-bandage) that generates HOCl in situ via precise polarization controlled by a miniaturized potentiostat was evaluated for the treatment of murine wound biofilm infections containing both P. aeruginosa with \"difficult-to-treat\" resistance and MRSA. Previously, HOCl-producing e-bandage was shown to reduce murine wound biofilms containing P. aeruginosa alone. Here, in 5-mm excisional skin wounds containing 48-h biofilms comprising MRSA and P. aeruginosa combined, polarized e-bandage treatment reduced MRSA by 1.1 log10 CFU/g (P = 0.026) vs non-polarized e-bandage treatment (no HOCl production), and 1.4 log10 CFU/g (0.0015) vs Tegaderm only controls; P. aeruginosa was similarly reduced by 1.6 log10 CFU/g (P = 0.0032) and 1.6 log10 CFU/g (P = 0.0015), respectively. For wounds infected with MRSA alone, polarized e-bandage treatment reduced bacterial load by 1.1 log10 CFU/g (P = 0.0048) and 1.3 log10 CFU/g (P = 0.0048) compared with non-polarized e-bandage and Tegaderm only, respectively. The e-bandage treatment did not negatively impact wound healing or cause tissue toxicity. The addition of systemic antibiotics did not enhance the antimicrobial efficacy of e-bandages. This study provides additional evidence for the HOCl-producing e-bandage as a novel antimicrobial strategy for managing wound infections, including in the context of antibiotic resistance and polymicrobial infections.
OBJECTIVE: New approaches are needed to combat the rise of antimicrobial-resistant infections. The HOCl-producing electrochemical bandage (e-bandage) leverages in situ generation of HOCl, a natural biocide, for broad-spectrum killing of wound pathogens. Unlike traditional therapies that may exhibit limited activity against biofilms and antimicrobial-resistant organisms, the e-bandage offers a potent, standalone solution that does not contribute to further resistance or require adjunctive antibiotic therapy. Here, we show the ability of the e-bandage to address polymicrobial infection by antimicrobial resistant clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa, two commonly isolated, co-infecting wound pathogens. Effectiveness of the HOCl-producing e-bandage in reducing pathogen load while minimizing tissue toxicity and avoiding the need for systemic antibiotics underscores its potential as a tool in managing complex wound infections.